MYOS RENS Technology Company Profile (NASDAQ:MYOS)

Analyst Ratings

Consensus Ratings for MYOS RENS Technology (NASDAQ:MYOS) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for MYOS RENS Technology (NASDAQ:MYOS)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for MYOS RENS Technology (NASDAQ:MYOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/13/2015        
11/17/2014($0.24)($0.73)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.20)($0.34)$1.68 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MYOS RENS Technology (NASDAQ:MYOS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for MYOS RENS Technology (NASDAQ:MYOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for MYOS RENS Technology (NASDAQ:MYOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/17/2016Zhengguang LyuDirectorBuy10,000$1.65$16,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2016Joseph MannelloDirectorBuy4,417$1.96$8,657.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Joseph MannelloDirectorBuy6,128$1.75$10,724.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2015Robert J. HaririDirectorBuy2,300$2.68$6,164.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Robert J. HaririDirectorBuy12,150$2.44$29,646.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015Robert J. HaririDirectorBuy4,000$1.73$6,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Robert J. HaririDirectorBuy25,250$1.71$43,177.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Louis J AronneDirectorBuy5,000$1.76$8,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Robert J HaririDirectorBuy2,750$1.74$4,785.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2014Robert J HaririDirectorBuy2,200$8.16$17,952.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Peter DiamandisDirectorBuy3,444$14.51$49,972.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for MYOS RENS Technology (NASDAQ:MYOS)
DateHeadline
06/29/16 03:17 PMMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/22/16 10:58 AMMYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 -
06/16/16 09:36 AMFDA approves minimally invasive AspireAssist weight loss device
05/20/16 04:26 PMMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant -
05/13/16 07:34 AMMYOS RENS TECHNOLOGY INC. Files SEC form 10-Q, Quarterly Report -
04/22/16 02:00 PMMYOS Reports Positive Results From Fortetropin(R) Clinical Study - [Marketwired] - MYOS RENS Technology Inc. , an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, ...
04/11/16 07:51 AMMYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q4, 2015 By the Numbers -
04/11/16 06:49 AMMYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: 2015 By the Numbers -
03/30/16 04:53 PMMYOS RENS TECHNOLOGY INC. Files SEC form 10-K, Annual Report -
03/23/16 04:21 AMMYOS Corporation Announces Corporate Name Change to MYOS RENS Technology Inc. - [at noodls] - CEDAR KNOLLS, NJ -- (Marketwired) -- 03/22/16 -- MYOS Corporation ('MYOS' or the 'Company') (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and ...
03/22/16 03:33 PMMYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ -
03/08/16 04:31 PMMYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Cha -
03/08/16 03:17 PMMYOS Corporation Announces Election of New Directors and Appointment of Ren Ren as Global Chairman - [Marketwired] - MYOS Corporation , an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced ...
02/12/16 01:47 PMRheumatoid arthritis market pipeline review H2 2015 published by leading research firm - Mitsubishi Tanabe Pharma Corporation, Modern Biosciences Plc, ModiQuest B.V., Momenta Pharmaceuticals, Inc., Morphotek, Inc., Mycenax Biotech Inc., Myos Corporation, Myungmoon pharmaceutical Co.,Ltd., NanoSmart Pharmaceuticals, Inc., Navigen ...
02/04/16 04:21 PMMYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events -
12/22/15 04:09 PMMYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation o -
12/21/15 03:32 PMMYOS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters -
12/17/15 12:55 PMWhy Are These Stocks Gaining Ground on Thursday? -
12/17/15 07:16 AMMYOS Corporation Announces Strategic Investment by RENS Technology Inc. - [at noodls] - CEDAR KNOLLS, NJ -- (Marketwired) -- 12/17/15 -- MYOS Corporation ('MYOS' or the 'Company') (NASDAQ: MYOS) Private placement of up to approximately $30.4 million, comprised of approximately $20.3 million ...
12/08/15 12:18 PMMYOS CORP Financials -
11/30/15 04:21 PMMYOS CORP Files SEC form 8-K, Other Events -
11/16/15 04:15 PMMYOS CORP Files SEC form 10-Q, Quarterly Report -
11/03/15 11:08 AMMYOS Corp. – Value Analysis (NASDAQ:MYOS) : November 3, 2015 -
10/26/15 06:55 AMMaintaining Muscle Linked to Preserving Healthy Brain Tissue - [at noodls] - Broad Implications for Muscle-Building Strategies in Managing Age-Related Cognitive Decline CEDAR KNOLLS, NJ -- (Marketwired) -- 10/26/15 -- MYOS Corporation ('MYOS' or the 'Company') (NASDAQ: MYOS), an ...
10/19/15 06:51 AMMYOS' Proprietary Muscle Building Technology Fortetropin: Foundation for New Dietary Recommendations - [at noodls] - A Paradigm Shift on the Importance of Healthy Fats in our Diet CEDAR KNOLLS, NJ -- (Marketwired) -- 10/19/15 -- MYOS Corporation ('MYOS' or the 'Company') (NASDAQ: MYOS), an emerging biotherapeutics and ...
10/02/15 09:53 AMMYOS Corp. Earnings Q2, 2015 -

Social

About MYOS RENS Technology

MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MYOS
  • CUSIP:
Key Metrics:
  • Previous Close: $1.73
  • 50 Day Moving Average: $1.90
  • 200 Day Moving Average: $1.76
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $8.79M
  • Beta: 1.21
  • Current Year EPS Consensus Estimate: $N/A EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links:
MYOS RENS Technology (NASDAQ:MYOS) Chart for Friday, July, 29, 2016